SCHEMBL3018723

SCHEMBL3018723

O=S(=O)(c1ccccc1Cl)C1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSS P25774 6/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
CCR1 P32246 1/20 0.37
NAAA Q02083 4/20 0.35
DRD4 P21917 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
GPR6 P46095 1/20 0.34
FPR2 P25090 2/20 0.34
PROKR1 Q8TCW9 2/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998651 0.94 CTSS (0.40) CTSSSMN1; SMN2RAB9ANPC1CCR1
SCHEMBL3012060 0.93 CTSS (0.41) CTSSSMN1; SMN2RAB9ANPC1CCR1
SCHEMBL3003682 0.93 CTSS (0.40) CTSSSMN1; SMN2RAB9ANPC1CCR1
SCHEMBL3017972 0.92 CTSS (0.38) CTSSSMN1; SMN2RAB9ANPC1CCR1
SCHEMBL3009939 0.92 CTSS (0.42) CTSSSMN1; SMN2RAB9ANPC1CCR1
SCHEMBL3009884 0.91 MAPT (0.36) CTSSSMN1; SMN2RAB9ANPC1DRD4
SCHEMBL3012591 0.91 CTSS (0.43) CTSSMEN1KMT2A
SCHEMBL3008760 0.90 CTSS (0.45) CTSSSMN1; SMN2RAB9ANPC1NAAA
SCHEMBL3010709 0.90 CTSS (0.37) CTSSSMN1; SMN2RAB9ADRD4SIGMAR1
SCHEMBL3010009 0.90 HTR2A (0.45) CTSSSMN1; SMN2RAB9ANPC1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.